Source: http://www.google.com/patents/US8114618?dq=U.S.+Patent+No.+4,528,643
Timestamp: 2016-05-05 22:45:11
Document Index: 741996851

Matched Legal Cases: ['Application No. 103948', 'Application No. 103948', 'Application No. 09168283', 'Application No. 103948', 'Application No. 103948', 'Application No. 103948', 'Application No. 103948', 'Application No. 2003', 'Application No. 2003']

Patent US8114618 - Measuring circulating therapeutic antibody, antigen and antigen/antibody ... - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsThe present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at...http://www.google.com/patents/US8114618?utm_source=gb-gplus-sharePatent US8114618 - Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assaysAdvanced Patent SearchPublication numberUS8114618 B2Publication typeGrantApplication numberUS 13/080,180Publication dateFeb 14, 2012Filing dateApr 5, 2011Priority dateSep 20, 2001Fee statusPaidAlso published asDE60233744D1, EP1438583A2, EP1438583A4, EP1438583B1, EP2131198A2, EP2131198A3, EP2131198B1, US7718387, US7943332, US8232068, US8501423, US8790882, US9157916, US20030068664, US20100221761, US20110236994, US20120107846, US20130004977, US20140011215, US20140335549, US20160069902, WO2003024993A2, WO2003024993A3Publication number080180, 13080180, US 8114618 B2, US 8114618B2, US-B2-8114618, US8114618 B2, US8114618B2InventorsMaher Albitar, Michael J. Keating, Taghi ManshouriOriginal AssigneeBoard Of Regents Of The University Of Texas SystemExport CitationBiBTeX, EndNote, RefManPatent Citations (14), Non-Patent Citations (49), Referenced by (6), Classifications (48), Legal Events (2) External Links: USPTO, USPTO Assignment, EspacenetMeasuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4376110Aug 4, 1980Mar 8, 1983Hybritech, IncorporatedImmunometric assays using monoclonal antibodiesUS5059522Aug 18, 1988Oct 22, 1991Wayne Lawrence GIntrinsic enzyme dot blot immunoassay or indentification of microorganismsUS5227159Jun 12, 1992Jul 13, 1993Miller Richard AAnti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodiesUS5234816Jul 12, 1991Aug 10, 1993Becton, Dickinson And CompanyMethod for the classification and monitoring of leukemiasUS5426029Nov 7, 1990Jun 20, 1995T Cell Diagnostics, Inc.Therapeutic and diagnostic methods using leukocyte surface antigensUS5525461Nov 1, 1991Jun 11, 1996T Cell Diagnostics, Inc.Therapeutic and diagnostic methods using total leukocyte surface antigensUS5597735Sep 2, 1994Jan 28, 1997Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health And WelfareGlycolipids for serodiagnosis of tuberculosis and leprosyUS5667981May 13, 1994Sep 16, 1997Childrens Hospital Of Los AngelesDiagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL proteinUS5700649Jun 5, 1995Dec 23, 1997Morton; Donald L.Method of detection of urinary tumor associated antigenUS5726064Sep 21, 1994Mar 10, 1998Applied Research Systems Ars Holding NvMethod of assay having calibration within the assayUS5736137Nov 3, 1993Apr 7, 1998Idec Pharmaceuticals CorporationTherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaUS6090365Nov 18, 1997Jul 18, 2000Coulter Pharmaceutical, Inc.Radioimmunotherapy of lymphoma using anti-CD20 antibodiesUS20020019018Jun 25, 2001Feb 14, 2002Christopherson Richard IanAssay to detect a binding partnerWO2000039580A1Dec 23, 1999Jul 6, 2000University Of SydneyAn assay to detect a binding partnerNon-Patent CitationsReference1"Diagnostic Tests, Evaluation of" In: Encyclopedia of Biostatistics, Armitage & Colton, Eds., John Wiley & Sons, Inc. vol. 2, pp. 1149-1155, 1998.2"Standard Error," In: Encyclopedia of Biostatistics, Armitage & Colton, Eds., John Wiley & Sons, vol. 6, p. 4232, Inc. , 1998.3Belov et al. "Immunophenotyping of leukemias using a cluster of differentiation antibody microarray" Cancer Res.; 61:4483-4489, 2001.4Binet, et al. "A clinical staging system for chronic lymphocytic leukemia" Cancer; 40:855-864, 1977.5Center for Drug Evaluation and Research, "Application No. 103948/0, Clinical pharmacology and Biopharmaceutics Review(s)," found at http:/lwww.fda.gov/cder/foi/nda/2000/1 03948-0000-Campath-ClinPharm.pdf, 2001.6Center for Drug Evaluation and Research, "Application No. 103948/0, Clinical pharmacology and Biopharmaceutics Review(s)," found at http:/lwww.fda.gov/cder/foi/nda/2000/1 03948—0000—Campath—ClinPharm.pdf, 2001.7Center for Drug Evaluation and Research, "Application No. NDA 21174, Clinical Pharmacology and Biopharmaceutics Review(s)," found at http://www.fda .gov/cder/foi/nda/2000/2 li 74-MYLOTARG-biopharmr. pdf, 2000.8Center for Drug Evaluation and Research, "Application No. NDA 21174, Clinical Pharmacology and Biopharmaceutics Review(s)," found at http://www.fda .gov/cder/foi/nda/2000/2 li 74—MYLOTARG—biopharmr. pdf, 2000.9Center for Drug Evaluation and Research, "Clinical Review of BLA Reference No. BLA 97-0260 and BLA 97-0244," found at http://www.fda.gov/cder/biologicslreview/ritugenl 12697-rl.pdf, 1997.10Dillman, "Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy," Cancer and Metastasis Reviews, 18:465-71, 1999.11Durrant, I. & Fowler, S., Chemiluminescent detection systems for protein blotting,In: Protein Blotting: A Practical Approach, Chapter 11, pp. 141-152, Dunbar, B.S., Ed., Oxford University Press, Inc., 1994.12Dyer et al., "Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype," Blood, 73:1431-1439, 1989.13Extended European Search Report, issued in European Application No. 09168283.1, mailed Jun. 4, 2010.14Ferrone, S. & Pellegrino, M.A. HL-A antigens, antibody, and complement in the lymphocytotoxic reaction, In: Contemporary Topics In Molecular Immunology, Reisfeld & Mandy , Eds. , Plenum Press, vol. 2, pp. 185-235, 1973.15Foran et al., "European phase II study of Rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphomas, immunocytoma, and small B-cell lymphocytic lymphoma," J. Clin. Oncol., 18:317-24, 2000.16Ginaldi, L. et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to CAMPATH-1H Leuk Res.;22:185-191, 1998.17Green et al, "Application No. 103948/0-Clinical Pharmacology and Biopharmaceutics Review(s)," retrieved from http://www.accessdata.fda.gov/drugsatfda-docs/nda/2000/103948-0000-CampathClinPharm.pdf, retrieved on Apr. 20, 2010.18Green et al, "Application No. 103948/0—Clinical Pharmacology and Biopharmaceutics Review(s)," retrieved from http://www.accessdata.fda.gov/drugsatfda—docs/nda/2000/103948—0000—CampathClinPharm.pdf, retrieved on Apr. 20, 2010.19Green et al, "Application No. 103948/0-Pharmacology Review," retrieved from http://www.accessdata.fda.gov/drugsatfda-docs/nda/2000/103948-0000-Campath-PharmTox.pdf, retrieved on Apr. 20, 2010.20Green et al, "Application No. 103948/0—Pharmacology Review," retrieved from http://www.accessdata.fda.gov/drugsatfda—docs/nda/2000/103948—0000—Campath—PharmTox.pdf, retrieved on Apr. 20, 2010.21Haisma et al., "Antibody-antigen complex formation following injection of OC125 monoclonal antibody in patients with ovarian cancer," Int. J. Cancer, 40:758-62, 1987.22Heegaard & Bjerrum, Immunoblotting-General Principles and Procedures, In: CRC Handbook of Immunoblotting Of Proteins, Bjerrum & Heegaard, Eds., CRC Press Inc., vol. 1, Section 1, pp. 1-25, 1988.23Heegaard & Bjerrum, Immunoblotting—General Principles and Procedures, In: CRC Handbook of Immunoblotting Of Proteins, Bjerrum & Heegaard, Eds., CRC Press Inc., vol. 1, Section 1, pp. 1-25, 1988.24Herold, M. et al. Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD 20 antibody rituximab Ann. Hematol., 2000;79:332-335.25Maheu, M. et al. Immunologic diagnosis and monitoring of human acute leukemias. Cancer, 40:855-64, 1977.26Manshouri et al., "Clinical Relevance of Circulating CD20 (cCD20) in Patients with Chronic Lymphocytic Leukemia (CLL)," Blood, 96(11): 369a, 2000 [abstract].27Manshouri et al., "Soluble CD52 is detectable in the plasma of patients with chronic lymphocyte leukemia," Blood, 98:149a, 2001.28McLaughlin et al, "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program," J. Clin. Oncol., 16:2825-33, 1998.29Milennium and ILEX Partners, LP: Campath 10-14 (Alemtuzumab), May 2, 2001, retrieved from http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088606.pdf, retrieved on Apr. 20, 2010.30Muniz, M. et al., "Protein sorting upon exit from the endoplasmic reticulum" Cell, 2001;104:313-320.31Nguyen et al., "IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients," Eur. J. Haematol., 62:76-82, 1999.32Office Action, issued in U.S. Appl. No. 10/251,144, dated Jul. 22, 2005.33Office Action, Japanese Application No. 2003-528839, mail dated Aug. 4, 2009.34Office Action, Japanese Application No. 2003-528839, mail dated Sep. 16, 2008.35Office Action,, issued in U.S. Appl. No. 10/251,144, dated Feb. 23, 2006.36Office Action,, issued in U.S. Appl. No. 10/251,144, dated Mar. 12, 2009.37Office Action,, issued in U.S. Appl. No. 10/251,144, dated Mar. 8, 2007.38Office Action,, issued in U.S. Appl. No. 10/251,144, dated Nov. 16, 2005.39Polliach et al., "Myelomonocytic Antigens are Rarely Expressed on B-Lymphocytic Leukemia Cells," Leukemia and Lymphoma, 9: 125-131, 1993.40Rai, K.R. et al. "Clinical staging of chronic lymphocytic leukemia" Blood, 1975;46:219-234.41Random House Webster's Unabridge Dictionary, 2nd Edition, New York, pp. 1242, 1998.42Reference Base, In: NIST/Sematech e-Handbook of Statistical Methods, Section 2.1.1.2, Croarkin, C. & Tobias, P., Eds., available at , retrieved Apr. 22, 2008.43Reference Base, In: NIST/Sematech e-Handbook of Statistical Methods, Section 2.1.1.2, Croarkin, C. & Tobias, P., Eds., available at <http://www.itl.nist.gov/div898/handbook/> , retrieved Apr. 22, 2008.44Rowan et al., "Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells," Immunology, 95:427-436, 1998.45Sakahara et al., "Effect of circulating antigen on immunoscintigraphy of ovarian cancer patients using anti-CA125 monoclonal antibody," Japan J. Cancer Res., 87:655-61, 1996.46Schrohenloher et al., "Circulating Antibody-Antigen complexes in human disease: possible occurrence in cancer," Ala. J. Med. Sci., 14:10-20, 1977.47Schrohenloher et al., "Circulating Antibody—Antigen complexes in human disease: possible occurrence in cancer," Ala. J. Med. Sci., 14:10-20, 1977.48Sievers, "Clinical studies of new "biologic" approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates," Curr. Opin. Oncol., 12:30-5, 2000.49Weiner, "An overview of monoclonal antibody therapy of cancer," Semin. Oncol., 26:41-50, 1999.Referenced byCiting PatentFiling datePublication dateApplicantTitleUS8232068 *Jan 12, 2012Jul 31, 2012Board Of Regents, The University Of Texas SystemMeasuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assaysUS8501423Jul 6, 2012Aug 6, 2013Board Of Regents, The University Of Texas SystemMeasuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assaysUS8790882Jul 3, 2013Jul 29, 2014Board Of Regents, The University Of Texas SystemMeasuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assaysUS9157916 *Jun 16, 2014Oct 13, 2015Board Of Regents, The University Of Texas SystemsMeasuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assaysUS20120107846 *Jan 12, 2012May 3, 2012Maher AlbitarMeasuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assaysUS20140335549 *Jun 16, 2014Nov 13, 2014Board Of Regents, The University Of Texas SystemMeasuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays* Cited by examinerClassifications U.S. Classification435/7.21, 427/337, 436/535, 530/350, 436/518, 427/338, 427/287, 435/4, 435/287.9, 436/501, 436/525, 530/300, 436/529, 436/809, 435/7.1International ClassificationG01N31/00, G01N33/574, G01N33/564, A61P13/08, A61P19/02, A61P35/00, A61P13/10, G01N33/53, A61P37/06, A61K39/395, A61P27/02, A61P35/02, A61P25/00, G01N33/577, A61P5/14, G01N33/543, A61P37/02Cooperative ClassificationG01N2800/52, C07K2317/24, G01N33/6872, G01N33/57492, C07K2317/76, C07K16/2887, G01N2333/70596, Y10T436/106664, Y10T436/107497, Y10S436/809, Y10S424/81, G01N33/564, G01N33/57407, G01N33/6893European ClassificationG01N33/564, G01N33/574CLegal EventsDateCodeEventDescriptionJun 5, 2013ASAssignmentOwner name: AWARE, INC., MASSACHUSETTSFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CUNNINGHAM, CHRISTOPHER CRAIG;REEL/FRAME:030547/0165Effective date: 20130604Aug 12, 2015FPAYFee paymentYear of fee payment: 4RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services